Irritable Bowel Syndrome (IBS)
Animal models are strong and some small human trials show reduced gut motility — but no IBS clinical benefit is proven yet.
Digestive Emerging
What the research says
The gut is densely populated with cannabinoid receptors, and animal models of IBS and visceral pain respond to cannabinoid modulation — that's the mechanistic promise. In humans, the trial record is thin and mostly null: a 2012 randomized, double-blind, placebo-controlled trial of dronabinol (synthetic THC) in 36 adults with diarrhea-predominant IBS found no overall effect on gastric, small bowel, or colonic transit — though it did find a genotype-dependent signal, with dronabinol preferentially slowing colon transit in people carrying a particular variant of the CNR1 cannabinoid-receptor gene. An earlier, smaller study had reported reduced fasting colonic motility. A 2020 review of the evidence for manipulating the endocannabinoid system in IBS reached the same measured conclusion: promising mechanisms, no proof of clinical benefit yet.
Patient surveys, meanwhile, report real symptom relief — usually cramping, pain, and the nausea side of IBS — which is why interest persists despite the thin trial base.
The honest caveats
IBS is a gut-brain disorder, so anything that changes stress and anxiety (which THC can, in both directions) will change symptoms — a big placebo effect in both directions. Two cautions: (1) THC can slow gut motility, which may help diarrhea-predominant IBS but could make constipation worse; (2) distinguish IBS from IBD — if there's inflammation, the IBD panel's warnings apply, and CHS is a real risk for heavy users with nausea-dominant symptoms.
Compounds to explore
These are the compounds — terpenes and cannabinoids — that the research connects to this condition. They are starting points for reading a COA or choosing a product, not prescriptions. Each has its own guide with more detail.
Cannabinoid THC The studied compound in IBS trials — it slowed colon motility in the lab but showed no overall symptom benefit in trials. Cannabinoid CBD Anti-inflammatory; largely untested for IBS specifically in humans. Terpene beta-caryophyllene Direct CB2 activity — relevant to gut inflammation and pain. Terpene alpha-terpineol Antispasmodic activity — the kind of effect that could matter for cramping; evidence is mostly preclinical.